On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage points to growth.
The Swiss pharma giant reported adjusted EPS of $2.06, up from $1.74 a year ago and beating the consensus of $1.96
Core operating profit for the third quarter grew to $5.15 billion from $4.41 billion the year prior.
Novartis generated $6 billion in free cash flow for the third quarter, up 18% year-over-year.
"All key growth drivers contributed to the momentum. We achieved important indications expansions for Kisqali in early breast cancer and Fabhalta in IgA nephropathy, and we completed our PSMAfore filing for Pluvicto in the US. With the momentum in our business and pipeline, we were able to once again upgrade our full-year guidance and remain highly confident in our mid-term outlook," said CEO Vas Narasimhan.
Quarterly Cosentyx sales gained 27% to $1.69 billion, driven by recent launches (including the HS indication and the IV formulation in the US) and volume growth in core indications.
Heart failure drug Entresto sales increased 26% to $1.87 billion, a demand-led growth. The drug has increased penetration in the U.S. and Europe following guideline-directed medical therapy for heart failure and in China with increased penetration in hypertension.
Multiple sclerosis drug Kesimpta sales reached $838 million, up +28%, reflecting increased demand for a high-efficacy product with convenient self-administered dosing.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a "high teens" percentage, compared with previous guidance of a "mid-to-high teens" percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Price Action: NVS stock is down 3.29% at $111.82 during the premarket session at the last check on Tuesday.
周二，诺华制药（NYSE:NVS）报告第三季度销售额为128.23亿美元，同比增长9%（按恒定货币计算增长10%），超过了127.6亿美元的市场共识。成交量为增长做出了12个百分点的贡献。
这家瑞士制药巨头报告调整后每股收益为2.06美元，高于去年的1.74美元，并超出了1.96美元的市场共识
第三季度核心营业利润从上一年的44.1亿美元增长到51.5亿美元。
诺华制药第三季度自由现金流达到了60亿美元，同比增长18%。
“所有主要增长驱动因素都为势头做出了贡献。我们在早期乳腺癌和IgA肾病的Kisqali获得了重要的适应症扩展，并为美国的Pluvicto提交了PSMAfore的申请。凭借我们的业务和研发管线的动力，我们再次调升了全年指引，并对中期前景充满信心，”首席执行官Vas Narasimhan表示。
季度Cosentyx销售额增长27%至16.9亿美元，受到最近推出的产品（包括在美国的HS适应症和静脉注射制剂）以及核心适应症的成交量增长的推动。
心力衰竭药物Entresto的销售额增长了26%至18.7亿美元，需求驱动增长。该药物在美国和欧洲在心力衰竭指导性医疗治疗后的渗透率增加，并在中国的高血压患者中的渗透率也有所提高。
多发性硬化症药物Kesimpta销售额达到83800万美元，增长28%，反映出对一种具有方便自行注射剂量且高效的产品需求增加。
指引：诺华制药今年再次上调其2024财年全年指引。
诺华制药在一份声明中表示，预计全年核心营业利润将增长高两位数百分比，相比之前的指引为中至上个两位数百分比。
诺华制药预测全年销售额增长低两位数百分比，此前指导为高个位到低两位数百分比的增长。
股价走势：NVS的股票在周二盘前交易中下跌3.29%，报111.82美元。
